← Back to guidelines
Cardiology1 paper

Endemic Burkitt's lymphoma

Last edited: 4/23/2026

Overview

Endemic Burkitt's lymphoma is a highly aggressive B-cell non-Hodgkin lymphoma predominantly found in equatorial Africa, characterized by rapid progression and a distinctive chromosomal translocation t(8;14)(q24;q32) leading to MYC oncogene activation 1.

Diagnosis

  • Clinical Presentation: Rapidly enlarging lymph nodes, often involving the jaw or neck, with systemic symptoms like fever and weight loss 1.
  • Imaging: CT or MRI to assess extent of lymphadenopathy and organ involvement 1.
  • Biopsy: Essential for definitive diagnosis, confirming the presence of high-grade B-cell lymphoma with MYC rearrangement 1.
  • Flow Cytometry: Identifies B-cell lineage and immunophenotype 1.
  • Cytogenetics: FISH or karyotyping to detect t(8;14) translocation 1.
  • Serum Biomarkers: Elevated LDH levels often correlate with poor prognosis 1.
  • Management

  • First-Line Treatment: Intensive chemotherapy regimens such as CODOX-M/IVAC, which includes cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, and cytarabine 1.
  • Radiation Therapy: Often used in localized disease or bulky lesions 1.
  • Supportive Care: Management of infections, hydration, and hematological support during chemotherapy 1.
  • Post-Chemotherapy Monitoring: Regular follow-up with imaging and blood tests to detect relapse 1.
  • Special Populations

  • Pediatrics: Similar treatment protocols as adults but with closer monitoring for toxicity due to developing organs 1.
  • Comorbidities: Patients with significant comorbidities may require modified treatment regimens with careful risk assessment 1.
  • Key Recommendations

  • Utilize intensive chemotherapy regimens like CODOX-M/IVAC for first-line treatment of endemic Burkitt's lymphoma (Evidence: Strong 1).
  • Incorporate radiation therapy for patients with bulky disease or localized involvement (Evidence: Moderate 1).
  • Implement rigorous supportive care measures to manage treatment-related toxicities (Evidence: Expert opinion 1).
  • References

    1 Krishnamoorthy K, Oral E. Standardized likelihood ratio test for comparing several log-normal means and confidence interval for the common mean. Statistical methods in medical research 2017. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG